Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics

Mark S Nestor, Glynis Ablon, Anita Gade, Haowei Han, Daniel L Fischer, Mark S Nestor, Glynis Ablon, Anita Gade, Haowei Han, Daniel L Fischer

Abstract

Background: Androgenetic alopecia (AGA) is the most common form of hair loss consisting of a characteristic receding frontal hairline in men and diffuse hair thinning in women, with frontal hairline retention, and can impact an individual's quality of life. The condition is primarily mediated by 5-alpha-reductase and dihydrotestosterone (DHT) which causes hair follicles to undergo miniaturization and shortening of successive anagen cycles. Although a variety of medical, surgical, light-based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select appropriate therapies for this chronic condition.

Aims: To highlight treatment options for androgenetic alopecia taking into consideration the efficacy, side effect profiles, practicality of treatment (compliance), and costs to help clinicians offer ethically appropriate treatment regimens to their patients.

Materials and methods: A literature search was conducted using electronic databases (Medline, PubMed, Embase, CINAHL, EBSCO) and textbooks, in addition to the authors' and other practitioners' clinical experiences in treating androgenetic alopecia, and the findings are presented here.

Results: Although topical minoxidil, oral finasteride, and low-level light therapy are the only FDA-approved therapies to treat AGA, they are just a fraction of the treatment options available, including other oral and topical modalities, hormonal therapies, nutraceuticals, PRP and exosome treatments, and hair transplantation.

Discussion: Androgenetic alopecia therapy remains challenging as treatment selection involves ethical, evidence-based decision-making and consideration of each individual patient's needs, compliance, budget, extent of hair loss, and aesthetic goals, independent of potential financial benefits to the practitioners.

Keywords: androgenetic alopecia; ethics; review; therapies; treatments.

Conflict of interest statement

Dr. Ablon is an investigator for Nutrafol and Viviscal.

© 2021 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.

References

    1. Giornale Italiano di Dermatologia e Venereologia 2014 February;149(1):15‐24. . Accessed February 1, 2021.
    1. Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs. 2016;76(14):1349‐1364.
    1. York K, Meah N, Bhoyrul B, Sinclair R. A review of the treatment of male pattern hair loss. Expert Opin Pharmacother. 2020;21(5):603‐612.
    1. Ethics and dermatology: finding harmony in daily practice ‐ practical dermatology. . Accessed March 25, 2021.
    1. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta‐analysis. J Am Acad Dermatol. 2017;77(1):136‐141.e5.
    1. Van Neste D, Fuh V, Sanchez‐Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804‐810.
    1. Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004;150(2):341‐345.
    1. Lolli F, Pallotti F, Rossi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9‐17.
    1. Mysore V, Parthasaradhi A, Kharkar RD, et al. Expert consensus on the management of androgenetic alopecia in India. Int J Trichology. 2019;11(3):101‐106.
    1. Wambier CG, Mehta N, Goren A, Cadegiani FA. COVID‐19, androgens, and androgenic alopecia. Dermatolog Rev. 2020;2(3):146‐153. 10.1002/der2.50
    1. Lee J, Yousaf A, Fang W, Kolodney MS. Male balding is a major risk factor for severe COVID‐19. J Am Acad Dermatol. 2020;83(5):e353‐e354.
    1. Wambier CG, Vaño‐Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID‐19: the “Gabrin sign”. J Am Acad Dermatol. 2020;83(2):680‐682.
    1. Wambier CG, Vaño‐Galván S, McCoy J, Pai S, Dhurat R, Goren A. Androgenetic alopecia in COVID‐19: compared to age‐matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020;83(6):e453‐e454.
    1. Ho CH, Sood T, Zito PM. Androgenetic alopecia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
    1. Sinclair R, Torkamani N, Jones L. Androgenetic alopecia: new insights into the pathogenesis and mechanism of hair loss. F1000Res. 2015;4(F1000 Faculty Rev):585.
    1. Kranz D. Young men’s coping with androgenetic alopecia: acceptance counts when hair gets thinner. Body Image. 2011;8(4):343‐348.
    1. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26(6):926‐931.
    1. Davis DS, Callender VD. Review of quality of life studies in women with alopecia. Int J Womens Dermatol. 2018;4(1):18‐22.
    1. Cranwell W, Sinclair R. Male androgenetic alopecia. In: Feingold KR, Anawalt B, Boyce A, et al, eds. Endotext. , Inc.; 2016.
    1. Rossi A, Anzalone A, Fortuna MC, et al. Multi‐therapies in androgenetic alopecia: review and clinical experiences. Dermatol Ther. 2016;29(6):424‐432.
    1. Kosman ME. Evaluation of a new antihypertensive agent. Minoxidil. JAMA. 1980;244(1):73‐75.
    1. Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open‐label and global photographic assessment. Dermatol Ther. 2020;10(6):1345‐1357.
    1. Blume‐Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia BN. A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126‐1134.e2.
    1. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999;41(5 Pt 1):717‐721.
    1. Marubayashi A, Nakaya Y, Fukui K, Li M, Arase S. Minoxidil‐induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001;117(6):1594‐1600. 10.1046/j.0022-202x.2001.01570.x
    1. Wester RC, Maibach HI, Guy RH, Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol. 1984;82(5):515‐517.
    1. De Villez RL. Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol. 1985;121(2):197‐202.
    1. Rundegren J. A one‐year observational study with minoxidil 5% solution in Germany: results of independent efficacy evaluation by physicians and patients. J Am Acad Dermatol. 2004;50(3):P91.
    1. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo‐controlled, double‐blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767‐774.
    1. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377‐385.
    1. Berger RS, Fu JL, Smiles KA, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149(2):354‐362.
    1. Ebner H, Müller E. Allergic contact dermatitis from minoxidil. Contact Dermat. 1995;32(5):316‐317. 10.1111/j.1600-0536.1995.tb00798.x
    1. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777‐2786.
    1. Goren A, Mccoy J, Kovacevic M, et al. The effect of topical minoxidil treatment on follicular sulfotransferase enzymatic activity. J Biol Regul Homeost Agents. 2018;32(4):937‐940.
    1. Gupta AK, Charrette A. Topical minoxidil: systematic review and meta‐analysis of its efficacy in androgenetic alopecia. Skinmed. 2015;13(3):185‐189.
    1. Olsen EA, Weiner MS. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol. 1987;17(1):97‐101. 10.1016/s0190-9622(87)70179-0
    1. Rossi A, Cantisani C, Melis L & Iorio A. Minoxidil use in dermatology, side effects and recent patents. Recent patents on. Published online 2012. Accessed February 10, 2021.
    1. Mirmirani P, Consolo M, Oyetakin‐White P, Baron E, Leahy P, Karnik P. Similar response patterns to topical minoxidil foam 5% in frontal and vertex scalp of men with androgenetic alopecia: a microarray analysis. Br J Dermatol. 2015;172(6):1555‐1561.
    1. Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842‐849.
    1. Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19‐27.
    1. Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. J Dermatolog Treat. 1997;8(3):189‐192.
    1. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47‐51.
    1. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1‐8.
    1. van Zuuren EJ, Fedorowicz Z. Interventions for female pattern hair loss. JAMA Dermatol. 2017;153(3):329‐330.
    1. Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4(6):1708‐1712. 10.1111/j.1743-6109.2007.00563.x
    1. Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128‐134.
    1. Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long‐term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol. 2008;18(4):400‐406.
    1. Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10‐year follow‐up. Dermatol Ther. 2011;24(4):455‐461.
    1. Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012;39(1):27‐32.
    1. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5‐alpha reductase inhibitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56‐62.
    1. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747‐1753. 10.1111/j.1743-6109.2011.02255.x
    1. Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9(11):2927‐2932. 10.1111/j.1743-6109.2012.02846.x
    1. Chiriacò G, Cauci S, Mazzon G, Trombetta C. An observational retrospective evaluation of 79 young men with long‐term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4(2):245‐250.
    1. Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo‐treated men with benign prostatic hyperplasia. Urology. 2003;61(3):579‐584. 10.1016/s0090-4295(02)02401-9
    1. Pereira AFJR, Coelho TOdA. Post‐finasteride syndrome. An Bras Dermatol. 2020;95(3):271‐277.
    1. Kiguradze T, Temps WH, Yarnold PR, et al. Persistent erectile dysfunction in men exposed to the 5α‐reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020.
    1. Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS. Sexual dysfunction in men taking systemic dermatologic medication: a systematic review. J Am Acad Dermatol. 2019;81(1):163‐172.
    1. Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220‐1223.
    1. Home ‐ welcome to the post‐finasteride foundation ‐ the post‐finasteride syndrome foundation. Published December 19, 2016. . Accessed February 24, 2021.
    1. O’Donnell L, Stanton PG, Wreford NG, Robertson DM, McLachlan RI. Inhibition of 5 alpha‐reductase activity impairs the testosterone‐dependent restoration of spermiogenesis in adult rats. Endocrinology. 1996;137(7):2703‐2710. 10.1210/endo.137.7.8770889
    1. Overstreet JW, Fuh VL, Gould J, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 1999;162(4):1295‐1300.
    1. Glina S, Neves PA, Saade R, Netto NR Jr, Soares JB, Galuppo AG. Finasteride‐associated male infertility. Rev Hosp Clin Fac Med Sao Paulo. 2004;59(4):203‐205.
    1. Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100(6):1542‐1546. 10.1016/j.fertnstert.2013.07.2000
    1. Simoni M, Huhtaniemi IT. Endocrinology of the Testis and Male Reproduction. Springer International Publishing; 2017.
    1. Arif T, Dorjay K, Adil M, Sami M. Dutasteride in androgenetic alopecia: an update. Curr Clin Pharmacol. 2017;12(1):31‐35.
    1. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α‐reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179‐2184. 10.1210/jc.2003-030330
    1. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α‐reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo‐controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014‐1023.
    1. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4(5):637‐640.
    1. Herz‐Ruelas ME, Álvarez‐Villalobos NA, Millán‐Alanís JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338‐345.
    1. Saceda‐Corralo D, Rodrigues‐Barata AR, Vañó‐Galván S, Jaén‐Olasolo P. Mesotherapy with dutasteride in the treatment of androgenetic alopecia. Int J Trichology. 2017;9(3):143‐145.
    1. Abdallah M, El‐Zawahry KA, Besar H. Mesotherapy using dutasteride‐containing solution in male pattern hair loss: a controlled pilot study. J Pan Arab Leag Dermatol. 2009;20:137‐145.
    1. Moftah N, Moftah N, Abd‐Elaziz G, et al. Mesotherapy using dutasteride‐containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686‐693. 10.1111/j.1468-3083.2012.04535.x
    1. Sobhy N, Aly H, El Shafee A, El Deeb M. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Derm Online. 2013;4(1):40‐45.
    1. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low‐dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104‐109.
    1. Vastarella M, Cantelli M, Patrì A, Annunziata MC, Nappa P, Fabbrocini G. Efficacy and safety of oral minoxidil in female androgenetic alopecia. Dermatol Ther. 2020;33(6):e14234.
    1. Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: tolerability & the five C’s of oral therapy. Dermatol Ther. 2018;31(6):e12707.
    1. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2020;84(3):737‐746. 10.1016/j.jaad.2020.06.1009
    1. Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female‐pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2020;82(1):252‐253.
    1. Jimenez‐Cauhe J, Saceda‐Corralo D, Rodrigues‐Barata R, et al. Effectiveness and safety of low‐dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2019;81(2):648‐649.
    1. Pirmez R, Salas‐Callo C‐I. Very‐low‐dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation. J Am Acad Dermatol. 2020;82(1):e21‐e22.
    1. Vañó‐Galván S, Pirmez R, Hermosa‐Gelbard A, et al. Safety of low‐dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644‐1651.
    1. Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013;5:541‐556.
    1. Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007;2(2):189‐199.
    1. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152(3):466‐473.
    1. Yazdabadi A, Green J, Sinclair R. Successful treatment of female‐pattern hair loss with spironolactone in a 9‐year‐old girl. Australas J Dermatol. 2009;50(2):113‐114.
    1. Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol. 2007;48(1):43‐45.
    1. Famenini S, Slaught C, Duan L, Goh C. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Dermatol. 2015;73(4):705‐706.
    1. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91‐95.
    1. Yazdabadi A, Sinclair R. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Australas J Dermatol. 2011;52(2):132‐134.
    1. Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011;45(4):469‐475.
    1. Johnson DB, Sonthalia S. Flutamide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
    1. Fernandez‐Nieto D, Saceda‐Corralo D, Rodrigues‐Barata R, et al. Oral bicalutamide for female pattern hair loss: a pilot study. Dermatol Ther. 2019;32(6):e13096.
    1. Fernandez‐Nieto D, Saceda‐Corralo D, Jimenez‐Cauhe J, et al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss. J Am Acad Dermatol. 2020;83(5):e355‐e356.
    1. Ismail FF, Meah N, Trindade de Carvalho L, Bhoyrul B, Wall D, Sinclair R. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol. 2020;83(5):1478‐1479.
    1. Kapadia N, Borhany T, Khalid G, Fatima A. Systemic cyproterone acetate and 5% minoxidil topical in the treatment of female pattern hair loss. J Pak Assoc Dermatol. 2009;19(4):216‐219.
    1. Coneac A, Muresan A, Orasan MS. Antiandrogenic therapy with ciproterone acetate in female patients who suffer from both androgenetic alopecia and acne vulgaris. Clujul Med. 2014;87(4):226‐234.
    1. Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. Br J Dermatol. 2002;146(6):992‐999.
    1. Eells JT, Wong‐Riley MTT, VerHoeve J, et al. Mitochondrial signal transduction in accelerated wound and retinal healing by near‐infrared light therapy. Mitochondrion. 2004;4(5–6):559‐567.
    1. Chung H, Dai T, Sharma SK, Huang Y‐Y, Carroll JD, Hamblin MR. The nuts and bolts of low‐level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516‐533.
    1. Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low‐level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46(2):144‐151.
    1. Lanzafame RJ, Blanche RR, Chiacchierini RP, Kazmirek ER, Sklar JA. The growth of human scalp hair in females using visible red light laser and LED sources. Lasers Surg Med. 2014;46(8):601‐607.
    1. Darwin E, Heyes A, Hirt PA, Wikramanayake TC, Jimenez JJ. Low‐level laser therapy for the treatment of androgenic alopecia: a review. Lasers Med Sci. 2018;33(2):425‐434.
    1. See how it works ‐ regrow your hair in 10 minutes per day. Published December 23, 2019. . Accessed March 8, 2021.
    1. RED light treatment for hair loss ‐ the science behind REVIAN RED. Published December 21, 2019. . Accessed March 8, 2021.
    1. Kernel Networks Inc . Modulated light therapy in participants with pattern hair loss. Case Med Res. 2019. 10.31525/ct1-nct04019795
    1. Esmat SM, Hegazy RA, Gawdat HI, et al. Low level light‐minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: a randomized controlled study. Lasers Surg Med. 2017;49(9):835‐843.
    1. Frigo L, Luppi JSS, Favero GM, et al. The effect of low‐level laser irradiation (In‐Ga‐Al‐AsP ‐ 660 nm) on melanoma in vitro and in vivo. BMC Cancer. 2009;9:404.
    1. Egger A, Resnik SR, Aickara D, et al. Examining the safety and efficacy of low‐level laser therapy for male and female pattern hair loss: a review of the literature. Skin Appendage Disord. 2020;6(5):259‐267.
    1. Girijala RL, Riahi RR, Cohen PR. Platelet‐rich plasma for androgenic alopecia treatment: a comprehensive review. Dermatol Online J. 2018;24(7):13030/qt8s43026c.
    1. Hausauer AK, Jones DH. Evaluating the efficacy of different platelet‐rich plasma regimens for management of androgenetic alopecia: a single‐center, blinded, randomized clinical trial. Dermatol Surg. 2018;44(9):1191‐1200.
    1. Hesseler MJ, Shyam N. Platelet‐rich plasma and its utilities in alopecia: a systematic review. Dermatol Surg. 2020;46(1):93‐102.
    1. Ha DH, Kim H‐K, Lee J, et al. Mesenchymal stem/stromal cell‐derived exosomes for immunomodulatory therapeutics and skin regeneration. Cells. 2020;9(5):1157. 10.3390/cells9051157
    1. Kwack MH, Seo CH, Gangadaran P, et al. Exosomes derived from human dermal papilla cells promote hair growth in cultured human hair follicles and augment the hair‐inductive capacity of cultured dermal papilla spheres. Exp Dermatol. 2019;28(7):854‐857.
    1. Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res. 2019;7:8.
    1. Rajendran RL, Gangadaran P, Bak SS, et al. Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice. Sci Rep. 2017;7(1):15560.
    1. Zhou L, Wang H, Jing J, Yu L, Wu X, Lu Z. Regulation of hair follicle development by exosomes derived from dermal papilla cells. Biochem Biophys Res Commun. 2018;500(2):325‐332.
    1. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5(1):6‐11.
    1. Ocampo‐Garza SS, Fabbrocini G, Ocampo‐Candiani J, Cinelli E, Villani A. Micro needling: a novel therapeutic approach for androgenetic alopecia, a review of literature. Dermatol Ther. 2020;33(6):e14267.
    1. Faghihi G, Nabavinejad S, Mokhtari F, Fatemi Naeini F, Iraji F. Microneedling in androgenetic alopecia; comparing two different depths of microneedles. J Cosmet Dermatol. 2021;20(4):1241‐1247. 10.1111/jocd.13714
    1. Kumar MK, Inamadar AC, Palit A. A randomized controlled, single‐observer blinded study to determine the efficacy of topical minoxidil plus microneedling versus topical minoxidil alone in the treatment of androgenetic alopecia. J Cutan Aesthet Surg. 2018;11(4):211‐216.
    1. Neerja P. A study on the efficacy of microneedling with minoxidil solution versus microneedling with hair multivitamin solution for the treatment of androgenetic alopecia. Int J Dermatol Clin Res. 2020;6(1):10‐12.
    1. Dhurat R, Mathapati S. Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. Indian J Dermatol. 2015;60(3):260‐263.
    1. Parajuli S, Paudel U. Microneedling for androgenetic alopecia not responding to conventional treatment. Our Dermatol Online. 2020;11(2):140‐142. 10.7241/ourd.20202.5
    1. Jha AK, Vinay K, Zeeshan M, Roy PK, Chaudhary RKP, Priya A. Platelet‐rich plasma and microneedling improves hair growth in patients ofandrogenetic alopecia when used as an adjuvant to minoxidil. J Cosmet Dermatol. 2019;18(5):1330‐1335. 10.1111/jocd.12864
    1. Greco J, Brandt R. The effects of autologus platelet rich plasma and various growth factors on non‐transplanted miniaturized hair. Hair Transplant Forum Int. 2009;19(2):49‐50.
    1. Middelkamp‐Hup MA, Bos JD, Rius‐Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow‐band UVB and oral polypodium leucotomos extract: a randomized double‐blind placebo‐controlled study. J Eur Acad Dermatol Venereol. 2007;21(7):942‐950.
    1. Choudhry SZ, Bhatia N, Ceilley R, et al. Role of oral polypodium leucotomos extract in dermatologic diseases: a review of the literature. J Drugs Dermatol. 2014;13(2):148‐153.
    1. Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol. Phytother Res. 2002;16(6):567‐571.
    1. Hosking A‐M, Juhasz M, Atanaskova MN. Complementary and alternative treatments for alopecia: a comprehensive review. Skin Appendage Disord. 2019;5(2):72‐89.
    1. Farris PK, Rogers N, McMichael A, Kogan S. A novel multi‐targeting approach to treating hair loss, using standardized nutraceuticals . J Drugs Dermatol. 2017;16(11):s141‐s148.
    1. Ablon G, Kogan S. A six‐month, randomized, double‐blind, placebo‐controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self‐perceived thinning hair. J Drugs Dermatol. 2018;17(5):558‐565.
    1. Ablon G, Kogan S. A randomized, double‐blind, placebo‐controlled study of a nutraceutical supplement for promoting hair growth in perimenopausal, menopausal, and postmenopausal women with thinning hair. J Drugs Dermatol. 2021;20(1):55‐61.
    1. Ablon G, Dayan S. A randomized, double‐blind, placebo‐controlled, multi‐center, extension trial evaluating the efficacy of a new oral supplement in women with self‐perceived thinning hair. J Clin Aesthet Dermatol. 2015;8(12):15‐21.
    1. Viviscal Elite Hair Care Club. . Accessed March 16, 2021.
    1. Lassus A, Eskelinen E. A comparative study of a new food supplement, ViviScal, with fish extract for the treatment of hereditary androgenic alopecia in young males. J Int Med Res. 1992;20(6):445‐453.
    1. Ablon G. A 6‐month, randomized, double‐blind, placebo‐controlled study evaluating the ability of a marine complex supplement to promote hair growth in men with thinning hair. J Cosmet Dermatol. 2016;15(4):358‐366.
    1. Ablon G. A 3‐month, randomized, double‐blind, placebo‐controlled study evaluating the ability of an extra‐strength marine protein supplement to promote hair growth and decrease shedding in women with self‐perceived thinning hair. Dermatol Res Pract. 2015;2015:841570.
    1. Glynis A. A double‐blind, placebo‐controlled study evaluating the efficacy of an oral supplement in women with self‐perceived thinning hair. J Clin Aesthet Dermatol. 2012;5(11):28‐34.
    1. Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair. . Accessed April 26, 2021.
    1. Murugusundram S. Serenoa repens: does it have any role in the management of androgenetic alopecia? J Cutan Aesthet Surg. 2009;2(1):31‐32.
    1. Kalwat JI. The use of serenoa repens (Saw Palmetto) in hair care products. Biomed J Sci Tech Res. 2019;13(1):9725–9728. 10.26717/bjstr.2019.13.002348
    1. Dhariwala MY, Ravikumar P. An overview of herbal alternatives in androgenetic alopecia. J Cosmet Dermatol. 2019;18(4):966‐975.
    1. Prager N, Bickett K, French N, Marcovici G. A randomized, double‐blind, placebo‐controlled trial to determine the effectiveness of botanically derived inhibitors of 5‐alpha‐reductase in the treatment of androgenetic alopecia. J Altern Complement Med. 2002;8(2):143‐152.
    1. Rossi A, Mari E, Scarno M, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two‐year study. Int J Immunopathol Pharmacol. 2012;25(4):1167‐1173.
    1. Ezekwe N, King M, Hollinger JC. The use of natural ingredients in the treatment of alopecias with an emphasis on central centrifugal cicatricial alopecia: a systematic review. J Clin Aesthet Dermatol. 2020;13(8):23‐27.
    1. Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed. 2015;13(1):15‐21.
    1. Cho YH, Lee SY, Jeong DW, et al. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double‐blind, placebo‐controlled trial. Evid Based Complement Alternat Med. 2014;2014:549721.
    1. Sakr FM, Gado AM, Mohammed HR, Adam ANI. Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. Drug Des Devel Ther. 2013;7:413‐423.
    1. Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatol Ther. 2020;33(1):e13202.
    1. Saraswat A. Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. Arch Dermatol. 2003;139(9):1219. 10.1001/archderm.139.9.1219-b
    1. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489‐498.
    1. Hu R, Xu F, Sheng Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol Ther. 2015;28(5):303‐308.
    1. Zhou Y, Chen C, Qu Q, et al. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta‐analysis. Dermatol Ther. 2020;33(4):e13741.
    1. Chandrashekar BS, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17‐20.
    1. Rafi AW, Katz RM. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatol. 2011;2011:241953.
    1. Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double‐blind, comparative study. J Med Assoc Thai. 2012;95(10):1312‐1316.
    1. Walsh DS, Dunn CL, James WD. Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride. Arch Dermatol. 1995;131(12):1373‐1375.
    1. Sharma A, Goren A, Dhurat R, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019;32(3):e12915.
    1. Abdel‐Raouf H, Aly UF, Medhat W, Ahmed SS, Abdel‐Aziz RTA. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatol Ther. 2021;34(1):e14678.
    1. Tanaka Y, Aso T, Ono J, Hosoi R, Kaneko T. Androgenetic alopecia treatment in Asian men. J Clin Aesthet Dermatol. 2018;11(7):32‐35.
    1. Faghihi G, Mozafarpoor S, Asilian A, et al. The effectiveness of adding low‐level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2018;84(5):547‐553.
    1. Munck A, Gavazzoni MF, Trüeb RM. Use of low‐level laser therapy as monotherapy or concomitant therapy for male and female androgenetic alopecia. Int J Trichology. 2014;6(2):45‐49.
    1. Leavitt M, Perez‐Meza D, Rao NA, Barusco M, Kaufman KD, Ziering C. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg. 2005;31(10):1268‐1276. discussion 1276.
    1. Alves R, Grimalt R. Platelet‐rich plasma in combination with 5% minoxidil topical solution and 1 mg oral finasteride for the treatment of androgenetic alopecia: a randomized placebo‐controlled, double‐blind, half‐head study. Dermatol Surg. 2018;44(1):126‐130. 10.1097/dss.0000000000001198
    1. Inamadar A, Kumar M, Palit A. A randomized controlled, single‐observer blinded study to determine the efficacy of topical minoxidil plus microneedling versus topical minoxidil alone in the treatment of androgenetic alopecia. J Cutan Aesthet Surg. 2018;11(4):211. 10.4103/jcas.jcas_130_17
    1. Bao L, Gong L, Guo M, et al. Randomized trial of electrodynamic microneedle combined with 5% minoxidil topical solution for the treatment of Chinese male androgenetic alopecia. J Cosmet Laser Ther. 2020;22(1):1‐7. 10.1080/14764172.2017.1376094
    1. Lee YB, Eun YS, Lee JH, et al. Effects of topical application of growth factors followed by microneedle therapy in women with female pattern hair loss: a pilot study. J Dermatol. 2013;40(1):81‐83.
    1. Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010;11(8):1295‐1304.
    1. Chouhan K, Roga G, Kumar A, Gupta J. Approach to hair transplantation in advanced grade baldness by follicular unit extraction: a retrospective analysis of 820 cases. J Cutan Aesthet Surg. 2019;12(4):215‐222.
    1. Pathomvanich D. Donor harvesting: a new approach to minimize transection of hair follicles. Dermatol Surg. 2000;26(4):345‐348. 10.1046/j.1524-4725.2000.99226.x
    1. Avram MR, Rogers N, Watkins S. Side‐effects from follicular unit extraction in hair transplantation. J Cutan Aesthet Surg. 2014;7(3):177‐179.
    1. Dua A, Dua K. Follicular unit extraction hair transplant. J Cutan Aesthet Surg. 2010;3(2):76‐81.
    1. Kayiran O, Cihandide E. Evolution of hair transplantation. Plast Aesthet Res. 2018;5(3):9.
    1. Tobin DJ. The aging hair pigmentary unit. In: Trüeb, RM , Tobin, DJ , eds.. Aging Hair. Heidelberg: Springer‐Verlag; 2010:77‐89. 10.1007/978-3-642-02636-2_9
    1. Sun HY, Sebaratnam DF. Clascoterone as a novel treatment for androgenetic alopecia. Clin Exp Dermatol. 2020;45(7):913‐914. 10.1111/ced.14292
    1. Yale K, Pourang A, Plikus MV, Mesinkovska NA. At the crossroads of 2 alopecias: androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors. JAAD Case Rep. 2020;6(5):444‐446.
    1. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):544‐547.
    1. Johnstone MA, Albert DM. Prostaglandin‐induced hair growth. Surv Ophthalmol. 2002;47(Suppl 1):S185‐S202.
    1. Blume‐Peytavi U, Lönnfors S, Hillmann K, Garcia BN. A randomized double‐blind placebo‐controlled pilot study to assess the efficacy of a 24‐week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794‐800.
    1. Stoff BK, Scully K, Housholder AL, Fabbro S, Kantor J. The American academy of dermatology (AAD) ethics pledge: i will put my patients’ welfare above all other interests, provide care that adheres to professional standards of practice, provide care for those in need, and foster collegiality through interaction with the medical community. J Am Acad Dermatol. 2016;75(2):445‐448.
    1. Gupta AK, Bamimore MA, Foley KA. Efficacy of non‐surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta‐analyses, and an assessment of evidence quality. J Dermatolog Treat. 2020:1‐11. Online ahead of print. 10.1080/09546634.2020.1749547
    1. Dhurat R, Chitallia J, May TW, et al. An open‐label randomized multicenter study assessing the noninferiority of a caffeine‐based topical liquid 0.2% versus minoxidil 5% solution in male androgenetic alopecia. Skin Pharmacol Physiol. 2017;30(6):298‐305.
    1. Alves R, Grimalt R. Randomized placebo‐controlled, double‐blind, half‐head study to assess the efficacy of platelet‐rich plasma on the treatment of androgenetic alopecia. Dermatol Surg. 2016;42(4):491.
    1. Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels. Endocr Rev. 2017;38(3):220‐254.
    1. Kohtz AS, Frye CA. Dissociating behavioral, autonomic, and neuroendocrine effects of androgen steroids in animal models. Methods Mol Biol. 2012;829:397‐431.
    1. Traish AM. Negative impact of testosterone deficiency and 5α‐reductase inhibitors therapy on metabolic and sexual function in men. Adv Exp Med Biol. 2017;1043:473‐526.
    1. Zito PM, Raggio BS. Hair transplantation. In: StatPearls. StatPearls Publishing; 2021.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться